REVIEW
|
doi:10.20944/preprints202304.0843.v2
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
CLL, Zanubrutinib, BTK inhibitors, efficacy, safety, chronic lymphocytic leukemia
Online: 22 May 2023 (16:15:16 CEST)
REVIEW
|
doi:10.20944/preprints202112.0282.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Acalabrutinib; Bruton’s tyrosine kinase; BTK; CLL; Covalent inhibitors; COVID-19; Ibrutinib; Non-covalent inhibitors; Fenebrutinib; MK1026; Pirtobrutinib; Spebrutinib; Tirabrutinib; Zanubrutinib
Online: 16 December 2021 (16:13:54 CET)
REVIEW
|
doi:10.20944/preprints202307.0990.v1
Subject:
Medicine And Pharmacology,
Neuroscience And Neurology
Keywords:
Bruton's tyrosine kinase (BTK); cognitive disorders; multiple sclerosis (MS); Neuroinflammation; immune system
Online: 14 July 2023 (13:24:12 CEST)
REVIEW
|
doi:10.20944/preprints202401.1747.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
chronic lymphocytic leukemia; BTK inhibitors; BCL-2 inhibitors; prognostic scores; predictive factors; TP53 abnormalities; IGHV; complex karyotype
Online: 24 January 2024 (13:39:51 CET)
REVIEW
|
doi:10.20944/preprints202112.0518.v1
Subject:
Biology And Life Sciences,
Immunology And Microbiology
Keywords:
B-cell non-Hodgkin lymphoma (B-NHL); B-cell receptor (BCR); Bruton’s tyrosine kinase (BTK); spleen tyrosine kinase (SYK); phosphoinositide-3-kinase (PI3K); ibrutinib; acalabrutinib; copanlisib; idelalisib; umbralisib; fostamatinib; combination therapies
Online: 31 December 2021 (12:23:29 CET)